The estimated Net Worth of Daniel Bazarko is at least $10.3 Millón dollars as of 17 December 2020. Mr Bazarko owns over 24,066 units of Alexion Pharmaceuticals stock worth over $10,060,063 and over the last 6 years he sold ALXN stock worth over $252,000.
Mr has made over 2 trades of the Alexion Pharmaceuticals stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 24,066 units of ALXN stock worth $2,816,685 on 17 December 2020.
The largest trade he's ever made was exercising 24,066 units of Alexion Pharmaceuticals stock on 17 December 2020 worth over $2,816,685. On average, Mr trades about 1,862 units every 48 days since 2019. As of 17 December 2020 he still owns at least 54,949 units of Alexion Pharmaceuticals stock.
You can see the complete history of Mr Bazarko stock trades at the bottom of the page.
Daniel A. Bazarko CPA is the Chief Accounting Officer & Sr. VP at Alexion Pharmaceuticals.
Daniel's mailing address filed with the SEC is C/O ALEXION PHARMACEUTICALS, INC., 121 SEAPORT BOULEVARD, BOSTON, MA, 02210.
Over the last 21 years, insiders at Alexion Pharmaceuticals have traded over $451,742,532 worth of Alexion Pharmaceuticals stock and bought 2,576,434 units worth $277,855,180 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Leonard Bell y Paul A Friedman. On average, Alexion Pharmaceuticals executives and independent directors trade stock every 9 days with the average trade being worth of $3,460,578. The most recent stock trade was executed by Daniel Bazarko on 17 December 2020, trading 24,066 units of ALXN stock currently worth $2,816,685.
Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent. In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.
Alexion Pharmaceuticals executives and other stock owners filed with the SEC include: